Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-30
2011-08-30
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S234100, C530S350000, C530S825000
Reexamination Certificate
active
08007812
ABSTRACT:
The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
REFERENCES:
patent: 5399494 (1995-03-01), Kaper et al.
patent: 6130082 (2000-10-01), Majarian et al.
patent: WO 93/18150 (1993-09-01), None
patent: 9929312 (1999-06-01), None
Ben-Yedidia et al. International immunology 11: 1043-1051, 1998.
Andreassen CN, et al., Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. 2003, Semin. Radiat. Oncol., vol. 13(1):62-72.
Bachmann, M.F., Wolint,P., Schwarz, K., and Oxenius, A. Recall proliferation potential of memory CD8+ T cells and antiviral protection. 2005, J. Immunol., vol. 175:4677-4685.
Carnes et al., Radiation Research. 2003, vol. 160(2):159-167 (Abstract Only).
Das, U.N., A Radical Approach to Cancer. 2002, Medical Science Monitor, vol. 8(4):RA79-RA92.
Eaves-Pyle TD, et al.,Salmonellaflagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. 2001, J. Immunol. vol. 12:7009-1016.
Efferson, C.L. et al., Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2
eu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. 2005 Anticancer Res. vol. 25:715-724.
Mutlu-Turkoglu U., et al., The effect of selenium and/or vitamin E treatments on radiation-induced intestinal injury in rats. 2000, Life Sci., vol. 66(20):1905-1913.
Patchen M.L., Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animals models. 1995, Eur. J. Cancer., 31A Suppl. 1: S17-21.
Satyamitra M., et al., In vivo postirradiation protection by a vitamin E analog, alpha-TMG. 2003, Radiat. Res. vol. 160(6):655-661.
Seed, T., et al., New strategies for the prevention of radiation injury: possible implications for countering radiation hazards of long-term space travel. 2002, J. Radiat. Res., vol. 43 Suppl:S239-244.
Spadaro, J.A., et al., Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone. 2005, Int. J. Radiat. Biol., vol. 10:759-765. (Abstract Only).
Sredini, B., et al., The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent. 1992, Int. J. Immunopharmacol., vol. 14(4):613-619.
Streeter, P.R., et al., Activation of the G-CSF and Flt-3 receptors protects hematopoietic stem cells from lethal irradiation. 2003, Exp. Hematol., vol. 31(11):1119-1125.
Symon, Z., et al., Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. 2001, Int. J. Radiat. Oncol. Biol. Phys., vol. 50(2):473-478.
Waddick, K.G., et al., In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. 1995, Blood, vol. 86(11):4228-4233.
Wheeler, C.M., Preventative vaccines for cervical cancer. 1997, Salud Publica de Mexico, vol. 39 No. 4.
Whitnall, M.H., et al., In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. 2001, Radiat. Res., vol. 156(3):283-293.
Wong, G.H., Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. 1995, Biochim. Biophys. Acta., vol. 1271(1):205-209.
Androstenediol and Androstenedione. Wikipedia. http://enwikipedia.org/wiki.
Grdina, D.J., Relationships between cytoprotection and mutation prevention by WR-1065. Feb. 2002, Military Medicine, vol. 167(2):51-53.
Murley, J.S. et al., Delayed cytoprotection after enhancement of Sod2 (MnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065, the active metabolite of amifostine. 2002, Radiation Res., vol. 158 (1):101-109.
Eaves-Pyles, T. et al., Flagellin, a novel mediator ofSalmonella-induced epithelial activation andsystemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. 2001, J. Immunol. vol. 166(2):1248-1260.
Kemp, G et al. Journal of Clinical Onocology (1996); 14(7): 2101-2112. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities; results of a randomized control in patients with advanced ovarian cancer.
Burdelya et al., “An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models,” Science Apr. 11, 2008, (320) pp. 226-230.
Hall, “Physics and Chemistry of Radiation Absorption,” Radiobiology for the Radiobiologist, pp. 5-15, 5th ed., Lippincott Williams and Wilkins, Phila., PA, 2000.
Carnes et al., Radiation Research 160(2): 159-167 (2003) (abstract only).
Bachmann, M.F., Wolint, P., Schwarz, K., and Oxenius, A. Recall proliferation potential of memory CD8+ T cells and antiviral protection. 2005 Journal of Immunology, vol. 175, pp. 4677-4685.
Das, U.N. A radical approach to cancer. 2002 Medical Science Monitor, vol. 8 No. 4, pp. RA79-RA92.
Efferson, C.L., Kawano, K., Tsuda, N., Palese, P., Garcia-Sastre, A., and Ioannides, C.G. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from HER-2
eu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. 2005 Anticancer Research vol. 25, pp. 715-724.
Wheeler, C.M. Preventative vaccines for cervical cancer. 1997, Salud Publica de Mexico, vol. 39. No. 4.
Androstenediol and Androstenedione. Wikipedia. http://en.wikipedia.org/wiki, Sep. 28, 2006.
Amendment after Final for U.S. Appl. No. 11/421,918 dated Mar. 16, 2009.
Final Rejection for U.S. Appl. No. 11/421,918 dated Mar. 10, 2009.
Supplemental Amendment for U.S. Appl. No. 11/421,918 dated Feb. 20, 2009.
Amendment After Non Final Rejection for U.S. Appl. No. 11/421,918 dated Jan. 23, 2009.
Non-Final Rejection for U.S. Appl. No. 11/421,918 dated Dec. 23, 2008.
Advisory Action for U.S. Appl. No. 11/421,918 dated Oct. 31, 2008.
Request for Continued Examination for U.S. Appl. No. 11/421,918 dated Oct. 10, 2008.
Final Rejection for U.S. Appl. No. 11/421,918 dated Apr. 11, 2008.
Amendment After Non Final Rejection for U.S. Appl. No. 11/421,918 dated Jan. 31, 2008.
Non Final Rejection for U.S. Appl. No. 11/421,918 dated Jan. 22, 2008.
Request for Continued Examination for U.S. Appl. No. 11/421,918 dated Nov. 12, 2007.
Final Rejection for U.S. Appl. No. 11/421,918 dated Aug. 13, 2007.
Amendment After Non Final Rejection for U.S. Appl. No. 11/421,918 dated Jun. 21, 2007.
Non Final Rejection for U.S. Appl. No. 11/421,918 dated Dec. 21, 2006.
DiDonato Joseph A.
Gudkov Andrei V.
Krivokrysenko Vadim
Cleveland Clinic Foundation
Devi S.
Galant Ron A.
Polsinelli Shughart PC
Scott, Jr. Teddy C.
LandOfFree
Flagellin related polypeptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flagellin related polypeptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flagellin related polypeptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782606